Analytics company Clarivate has released its 2026 Drugs to Watch report, with eleven therapies expected to deliver clinical and commercial impact this coming year. 

The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform care within five years. 

Drawing on Clarivate integrated data assets and AI-powered intelligence, the analysis reflects the interplay of scientific progress, regulatory change and evolving competitive dynamics as companies navigate increasingly complex global markets. 

The report pinpoints drugs that treat obesity, asthma, multiple sclerosis and breast cancer, with Eli Lilly and Johnson & Johnson leading the way with two separate drugs featured on the list. 

According to the report, delivery innovation will be increasingly important in 2026, including extended-release formulations and oral alternatives to injectable drugs, which improve adherence and real-world outcomes.  

Meanwhile, mainland China is emerging as both a critical commercial market and a source of global innovation, with domestic developers advancing competitive therapies that are shaping global strategies in oncology, metabolic disease and immunology. 

“The pharmaceutical landscape in 2026 will be defined by both unprecedented innovation and increasing complexity,” said Henry Levy, Life Sciences & Healthcare at Clarivate. 

“From metabolic disease to rare conditions and precision therapies, the ability to anticipate emerging drug trends and understand shifting patient and market dynamics will be critical.  

“This year’s Drugs to Watch report highlights not only therapies with the potential to transform care but also the broader trends shaping the industry. By leveraging anticipatory intelligence and advanced analytics, companies can make more informed decisions, prioritise meaningful innovation and ultimately bring transformative treatments to patients faster.”